StockData
Immunome Inc. logo

Immunome Inc. (IMNM) stock

IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$16.61−0.17 (-1.01%)

Close on Nov 19, 2026Market cap $1.89BP/E –Yield –

Immunome free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Immunome's free cash flow for the twelve months ending Mar 31, 2026 was -$205.52M. For fiscal 2025 it was -$200.60M. The highest annual figure on record is -$8.40M in fiscal 2023.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$200.60M–
FY2024Dec 31, 2024-$117.97M–
FY2023Dec 31, 2023-$8.40M–
FY2022Dec 31, 2022-$28.94M–
FY2021Dec 31, 2021-$18.31M–
FY2020Dec 31, 2020-$12.72M–
FY2019Dec 31, 2019-$9.83M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026-$61.64M–
Q4 FY2025Dec 31, 2025-$51.95M–
Q3 FY2025Sep 30, 2025-$41.63M–
Q2 FY2025Jun 30, 2025-$50.31M–
Q1 FY2025Mar 31, 2025-$56.72M–
Q4 FY2024Dec 31, 2024-$43.19M–
Q3 FY2024Sep 30, 2024-$35.71M–
Q2 FY2024Jun 30, 2024-$25.74M–
Q1 FY2024Mar 31, 2024-$13.33M-155.4%
Q4 FY2023Dec 31, 2023-$17.81M–
Q3 FY2023Sep 30, 2023-$8.65M–
Q2 FY2023Jun 30, 2023-$6.01M–
Q1 FY2023Mar 31, 2023$24.07M–
Q4 FY2022Dec 31, 2022-$6.76M–
Q3 FY2022Sep 30, 2022-$7.57M–
Q2 FY2022Jun 30, 2022-$8.23M–
Q1 FY2022Mar 31, 2022-$6.38M–
Q4 FY2021Dec 31, 2021-$6.82M–
Q3 FY2021Sep 30, 2021-$4.17M–
Q2 FY2021Jun 30, 2021-$3.75M–
Q1 FY2021Mar 31, 2021-$3.57M–
Q4 FY2020Dec 31, 2020-$6.11M–
Q3 FY2020Sep 30, 2020-$2.65M–
Q2 FY2020Jun 30, 2020-$1.84M–
Q1 FY2020Mar 31, 2020-$2.12M–
Q4 FY2019Dec 31, 2019-$2.65M–

More Immunome figures

See a number that looks wrong?